Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors
Fabian P. Suchy(California Institute for Regenerative Medicine), Hiromitsu Nakauchi(University of Tsukuba), Maimi Higuchi(Stanford University), Carsten T. Charlesworth(Stanford University), Jinyu Zhang(Shanghai University of Traditional Chinese Medicine), Mark A. Kay(Io Therapeutics (United States)), Ian Hsu(University of Oxford), Daiki Karigane(Keio University), Amy C. Fan(Stanford University), Katja Pekrun(Pediatrics and Genetics), Adam C. Wilkinson(Wellcome/MRC Cambridge Stem Cell Institute), Ravindra Majeti(Stanford University), Toshinobu Nishimura(Stanford University), T. Nishimura(Hokkaido University), Yusuke Nakauchi(Stanford University), Joydeep Bhadury(Stanford University)
Cited by 56
Related Papers
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
|Science Translational Medicine|2017|427
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
|Proceedings of the National Academy of Sciences|2012|256
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers
|Hepatology|2012|195